Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bertoli, Hanna Kristina ; Baandrup, Louise ; Aalborg, Gitte Lerche ; Kjaer, Alexander K ; Thomsen, Louise T ; Kjaer, Susanne K. / Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study. In: Gynecologic Oncology. 2020 ; Vol. 158, No. 3. pp. 734-739.

Bibtex

@article{094cdc66e94f42f18a17683e7783edd6,
title = "Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study",
abstract = "Objective: To describe trends in incidence of high-grade vaginal intraepithelial neoplasia (VaIN) and vaginal squamous cell carcinoma (SCC) in Denmark. For vaginal SCC, we also examine 5-year relative survival and mortality. Methods: All high-grade VaIN cases diagnosed 1997–2017 and vaginal SCCs during 1978–2017 were identified in two high-quality nationwide registers. Age-standardized incidence rates and average annual percentage change (AAPC) were assessed. For vaginal SCC, 5-year relative survival was calculated, and Cox regression was applied to study the effect of selected characteristics on mortality. Results: Altogether, 831 cases of high-grade VaIN and 721 vaginal SCCs were identified. The age-standardized incidence rate of high-grade VaIN showed no clear trend over time. However, when we stratified by age and divided the study period according to HPV vaccine licensure in Denmark (2006), the incidence of high-grade VaIN decreased significantly by 15.6% per year (95% CI: −23.2, −7.3%) after 2007 onwards among the youngest women (<30 years). For vaginal SCC, the incidence decreased from 0.5 (1978–1982) to 0.3 (2013–2017) per 100,000 woman-years. The 5-year relative survival improved over time and was 67.9% (95% CI: 54.9, 84.1%) in the most recent time period. Mortality was significantly associated with calendar year, age, and stage at diagnosis. Conclusions: The overall incidence of high-grade VaIN showed no clear trend over time, but a significant decline was observed in women younger than 30 years after HPV vaccine licensure. The incidence of vaginal SCC was reduced by approximately 50% and survival after vaginal SCC improved over time.",
keywords = "Incidence, Relative survival, Vaginal cancer, VaIN",
author = "Bertoli, {Hanna Kristina} and Louise Baandrup and Aalborg, {Gitte Lerche} and Kjaer, {Alexander K} and Thomsen, {Louise T} and Kjaer, {Susanne K}",
note = "Copyright {\textcopyright} 2020 Elsevier Inc. All rights reserved.",
year = "2020",
month = sep,
day = "1",
doi = "10.1016/j.ygyno.2020.05.683",
language = "English",
volume = "158",
pages = "734--739",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "3",

}

RIS

TY - JOUR

T1 - Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study

AU - Bertoli, Hanna Kristina

AU - Baandrup, Louise

AU - Aalborg, Gitte Lerche

AU - Kjaer, Alexander K

AU - Thomsen, Louise T

AU - Kjaer, Susanne K

N1 - Copyright © 2020 Elsevier Inc. All rights reserved.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - Objective: To describe trends in incidence of high-grade vaginal intraepithelial neoplasia (VaIN) and vaginal squamous cell carcinoma (SCC) in Denmark. For vaginal SCC, we also examine 5-year relative survival and mortality. Methods: All high-grade VaIN cases diagnosed 1997–2017 and vaginal SCCs during 1978–2017 were identified in two high-quality nationwide registers. Age-standardized incidence rates and average annual percentage change (AAPC) were assessed. For vaginal SCC, 5-year relative survival was calculated, and Cox regression was applied to study the effect of selected characteristics on mortality. Results: Altogether, 831 cases of high-grade VaIN and 721 vaginal SCCs were identified. The age-standardized incidence rate of high-grade VaIN showed no clear trend over time. However, when we stratified by age and divided the study period according to HPV vaccine licensure in Denmark (2006), the incidence of high-grade VaIN decreased significantly by 15.6% per year (95% CI: −23.2, −7.3%) after 2007 onwards among the youngest women (<30 years). For vaginal SCC, the incidence decreased from 0.5 (1978–1982) to 0.3 (2013–2017) per 100,000 woman-years. The 5-year relative survival improved over time and was 67.9% (95% CI: 54.9, 84.1%) in the most recent time period. Mortality was significantly associated with calendar year, age, and stage at diagnosis. Conclusions: The overall incidence of high-grade VaIN showed no clear trend over time, but a significant decline was observed in women younger than 30 years after HPV vaccine licensure. The incidence of vaginal SCC was reduced by approximately 50% and survival after vaginal SCC improved over time.

AB - Objective: To describe trends in incidence of high-grade vaginal intraepithelial neoplasia (VaIN) and vaginal squamous cell carcinoma (SCC) in Denmark. For vaginal SCC, we also examine 5-year relative survival and mortality. Methods: All high-grade VaIN cases diagnosed 1997–2017 and vaginal SCCs during 1978–2017 were identified in two high-quality nationwide registers. Age-standardized incidence rates and average annual percentage change (AAPC) were assessed. For vaginal SCC, 5-year relative survival was calculated, and Cox regression was applied to study the effect of selected characteristics on mortality. Results: Altogether, 831 cases of high-grade VaIN and 721 vaginal SCCs were identified. The age-standardized incidence rate of high-grade VaIN showed no clear trend over time. However, when we stratified by age and divided the study period according to HPV vaccine licensure in Denmark (2006), the incidence of high-grade VaIN decreased significantly by 15.6% per year (95% CI: −23.2, −7.3%) after 2007 onwards among the youngest women (<30 years). For vaginal SCC, the incidence decreased from 0.5 (1978–1982) to 0.3 (2013–2017) per 100,000 woman-years. The 5-year relative survival improved over time and was 67.9% (95% CI: 54.9, 84.1%) in the most recent time period. Mortality was significantly associated with calendar year, age, and stage at diagnosis. Conclusions: The overall incidence of high-grade VaIN showed no clear trend over time, but a significant decline was observed in women younger than 30 years after HPV vaccine licensure. The incidence of vaginal SCC was reduced by approximately 50% and survival after vaginal SCC improved over time.

KW - Incidence

KW - Relative survival

KW - Vaginal cancer

KW - VaIN

UR - http://www.scopus.com/inward/record.url?scp=85086517745&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2020.05.683

DO - 10.1016/j.ygyno.2020.05.683

M3 - Journal article

C2 - 32571683

VL - 158

SP - 734

EP - 739

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -

ID: 61556412